Clinical Trial Update: Efficacy Study of Vx001 Vaccine in NSCLC Patients [Phase 2]

View source ↗

Summary

Phase 2 efficacy study of Vx001 vaccine in metastatic non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Vx001 vaccine (Vx001 vaccine)

Snippet

Sponsor: Vaxon Biotech | Conditions: Non-small Cell Lung Cancer Metastatic | Phase 2 | Status: COMPLETED